Advanced-Stage Laryngeal CA Outcomes Better at LSU Health

This article originally appeared here.
Share this content:
Advanced-Stage Laryngeal CA Outcomes Better at LSU Health
Advanced-Stage Laryngeal CA Outcomes Better at LSU Health

(HealthDay News) -- Patients with advanced-stage laryngeal cancer treated at Louisiana State University Health-Shreveport (LSU Health) have higher survival rates, according to a study published online Nov. 27 in JAMA Otolaryngology-Head & Neck Surgery.

Blake Joseph LeBlanc, M.D., from LSU Health, and colleagues compared survival outcomes for initial surgical treatment of advanced-stage primary tumors. The authors identified patients diagnosed as having laryngeal carcinoma between 1998 and 2007. Data for 165 patients treated at LSU Health and national data were obtained from the National Cancer Database.

The researchers found that 70.91 percent of patients presented with advanced-stage (III/IV) disease at LSU Health, compared with 46.67 percent nationwide (P < 0.01). The five-year survival rate was 55.54 percent for stage IV disease, compared with 31.60 percent nationwide (P < 0.05). More LSU Heath patients were uninsured (23.73 versus 5.05 percent nationally; P < 0.001), and more patients traveled further distances for care (60.74 percent traveling 50 miles or more versus 15.87 percent nationally; P < 0.001). Overall, 54.70 percent of patients with advanced-stage disease underwent primary surgery to include total laryngectomy; the rate of laryngectomy decreased from 40 to 60 percent in the 1980s to 32 percent in 2007.

"We believe that upfront laryngectomy may explain our higher survival rates for advanced-stage laryngeal cancer," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »